Skip to content
Ilaris(canakinumab)
Ilaris (canakinumab) is an antibody pharmaceutical. Canakinumab was first approved as Ilaris on 2009-06-17. It is used to treat cryopyrin-associated periodic syndromes, familial mediterranean fever, juvenile arthritis, and mevalonate kinase deficiency in the USA. It has been approved in Europe to treat cryopyrin-associated periodic syndromes, gouty arthritis, and juvenile arthritis. The pharmaceutical is active against interleukin-1 beta.
Download report
Favorite
COVID-19
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ilaris
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Canakinumab
Tradename
Proper name
Company
Number
Date
Products
IlariscanakinumabNovartis Pharmaceuticals CorporationN-125319 RX2016-12-22
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ilarisBiologic Licensing Application2020-09-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cryopyrin-associated periodic syndromesD056587M04.2
familial mediterranean feverD010505M04.1
juvenile arthritisEFO_0002609D001171M08
mevalonate kinase deficiencyD054078M04.1
Agency Specific
FDA
EMA
Expiration
Code
canakinumab, Ilaris, Novartis Pharmaceuticals Corporation
2027-06-16Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AC: Interleukin inhibitors
L04AC08: Canakinumab
HCPCS
Code
Description
J0638
Injection, canakinumab, 1 mg
Clinical
Clinical Trials
102 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.92617
Psoriatic arthritisD015535EFO_0003778L40.511
SpondylarthritisD02524111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Juvenile arthritisD001171EFO_0002609M081178
Gouty arthritisD015210257
Cryopyrin-associated periodic syndromesD056587M04.277
Non-small-cell lung carcinomaD0022891236
Type 2 diabetes mellitusD003924EFO_0001360E11425
Adult-onset still's diseaseD016706EFO_0007135M06.1112
Cytokine release syndromeD000080424D89.83112
AtherosclerosisD050197EFO_0003914I25.1112
Lung neoplasmsD008175C34.90112
Pancreatic neoplasmsD010190EFO_0003860C2511
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D46234
Schnitzler syndromeD019873EFO_100116533
Covid-19D000086382U07.1112
Type 1 diabetes mellitusD003922EFO_0001359E1022
MelanomaD00854511
Familial mediterranean feverD010505M04.111
GoutD006073EFO_0004274M1011
Glucose intoleranceD018149HP_0000833R73.0311
Knee osteoarthritisD020370EFO_0004616M1711
Alzheimer diseaseD000544EFO_0000249F0311
Show 29 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD06472622
Pancreatic ductal carcinomaD02144111
Renal cell carcinomaD00229211
Macular degenerationD008268EFO_0001365H35.3011
Healthy volunteers/patients11
FeverD005334HP_0001945R50.911
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCANAKINUMAB
INNcanakinumab
Description
Immunoglobulin G1, anti-[Homo sapiens interleukin 1, beta (IL1B)] human monoclonal ACZ885; gamma1 heavy chain (Homo sapiens VH-IGHG1*03) (221-214’)-disulfide with kappa light chain (Homo sapiens V-KAPPA-IGKC*01); (227-227’’:230-230’’)-bisdisulfide dimer
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)CANAKINUMAB
Structure (InChI/SMILES or Protein Sequence)
>4G5Z:H|canakinumab antibody fragment heavy chain QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPAKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLY LQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVAP >4G5Z:L|canakinumab antibody fragment light chain EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEA EDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
Identifiers
PDB4G5Z, 4G6J, 5BVJ, 5BVP
CAS-ID914613-48-2
RxCUI853491
ChEMBL IDCHEMBL1201834
ChEBI ID
PubChem CID
DrugBankDB06168
UNII ID37CQ2C7X93 (ChemIDplus, GSRS)
Target
Agency Approved
IL1B
IL1B
Organism
Homo sapiens
Gene name
IL1B
Gene synonyms
IL1F2
NCBI Gene ID
Protein name
interleukin-1 beta
Protein synonyms
Catabolin, IL-1 beta, interleukin 1beta, preinterleukin 1 beta, pro-interleukin-1-beta
Uniprot ID
Mouse ortholog
Il1b (16176)
interleukin-1 beta (Q2M4J6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ilaris - Novartis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,397 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,849 adverse events reported
View more details